Lotte M. Knapen

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

Nienke A. G. Lankheet, Lotte M. Knapen, Jan H.M. Schellens et al. · Therapeutic Drug Monitoring · 2013 · 106 citations

Medicine, Oncology, Pharmacology +14

Use of incretin agents and risk of pancreatic cancer: a population‐based cohort study

Lotte M. Knapen, Judith van Dalem, Yolande C.A. Keulemans et al. · Diabetes Obesity and Metabolism · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacology +10

Use of incretin agents and risk of acute and chronic pancreatitis: A population‐based cohort study

Lotte M. Knapen, Roy G.P.J. de Jong, Johanna H. M. Driessen et al. · Diabetes Obesity and Metabolism · 2016 · 40 citations · Full text

Medicine, Internal Medicine, Pharmacology +15

Development and validation of an analytical method using UPLC–MS/MS to quantify everolimus in dried blood spots in the oncology setting

Lotte M. Knapen, Yvo de Beer, Roger J. M. Brüggemann et al. · Journal of Pharmaceutical and Biomedical Analysis · 2017 · 33 citations · Full text

Medicine, Hematology, Oncology +9

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer

Annelieke E.C.A.B. Willemsen, Lotte M. Knapen, Yvo M. de Beer et al. · European Journal of Clinical Pharmacology · 2017 · 25 citations · Full text

Pharmacy, Oncology, Pharmacology +13